Supernus Pharmaceuticals, Inc.
SUPNHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Supernus Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United. At a $2.37B market cap, Supernus Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Market Cap
$2.37B
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
9.51
EPS (TTM)
$-1.92
EPS (Fwd)
$4.28
ROE
-10.5%
ROA
0.4%
Cash
$372.1M
Total Debt
$40.2M
Free CF
$84.6M
52W Change
-22.8%
Annual Financials
Cash vs Debt
Where SUPN stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, SUPN finished 18.75% below its 150-day moving average ($46.62) and 20.69% below its 200-day moving average ($47.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SUPN overbought or oversold?
At the October 19, 2026 close, SUPN's RSI(14) was 15.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $372.1M in cash comfortably exceeding the $40.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $84.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -10.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $667.2M (2022) to $719.0M (2025).
The relatively low beta of 0.55 suggests SUPN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SUPN.